Member of the Financial Accounting Standards Foundation

Disclaimer: This is a Japanese-English translation of the summary of financial statements of the Company produced for your convenience. Since no auditor audited this report, officially only the Japanese version is assumed to be the summary of financial statements of the Company. This summary does not constitute any guarantee and the Company will not compensate any losses and/or damage stemming from actions taken based on these statements. Should there be any discrepancy between the Japanese and English versions, the Japanese version is assumed to be correct.

November 11, 2026

Consolidated Earnings Report for the First Six Month of Fiscal 2026 [Japanese GAAP]

Company Name: BML, Inc.
Stock Listing: Tokyo Stock Exchange
Stock Code: 4694
URL: https://www.bml.co.jp
Representative: Kensuke Kondo, President and Representative Director
Contact: Norihisa Takebe,
Representative Director and Senior Managing Executive Officer
Tel: +81-3-3350-0111

Scheduled Date for Filing of Semi-annual Securities Report: November 13, 2026
Scheduled Date for Payment of Dividends: December 2, 2026
Creation of Supplementary Explanatory Materials: Yes
Holding of Explanatory Meeting: Yes

(Rounded down to nearest million yen)

1. Results for the First Six Month of Fiscal 2026 (April 1, 2026– September 30, 2026)

(1) Consolidated business results

(% indicates year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	¥ million	%	¥ million	%	¥ million	%	¥ million	%
First six month of FY2026	78,038	3.2	6,046	2.2	6,335	3.5	4,010	(4.9)
First six month of FY2025	75,628	6.0	5,915	14.4	6,118	14.2	4,219	23.1

(Note) Comprehensive income: First six month of FY2026 ¥4,070 million / (8.7)%
First six month of FY2025 ¥4,455 million / 27.8%

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
First six month of FY2026	106.98	106.94
First six month of FY2025	109.38	109.34

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
	¥ million	¥ million	%
As of September 30, 2026	182,441	133,748	70.8
As of March 31, 2026	183,247	132,129	69.7

(Reference) Equity capital: As of September 30, 2026 ¥129,258 million As of March 31, 2026 ¥127,646 million

2. Dividends

	Dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Year-end	Full year
	Yen	Yen	Yen	Yen	Yen
FY2025	–	60.00	–	65.00	125.00
FY2026	–	62.50			
FY2026 (forecast)			–	62.50	125.00

(Note) Revision of dividend projection from recently announced figures: None

3. Consolidated Cumulative Earnings Forecast for the Fiscal Year Ending March 31, 2027 (April 1, 2026–March 31, 2027)

(% indicates year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	¥ million	%	¥ million	%	¥ million	%	¥ million	%	Yen
Full year	155,000	3.2	10,500	0.8	11,000	(0.1)	7,000	(9.7)	186.75

(Note) Revision from recently projected results: None

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None

Newly included: - companies (Company name:)

Excluded: - companies (Company name:)

(2) Adoption of accounting treatment specific to the preparation of semi-annual consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

1) Changes in accounting policies due to revisions to accounting standards and other regulations: None

2) Changes in accounting policies due to other reason: None

3) Changes in accounting estimates: None

4) Restatement: None

(4) Number of outstanding shares (common shares)

a. Number of outstanding shares at the end of the period (treasury shares included)

As of September 30, 2026	40,749,426	As of March 31, 2026	40,749,426

b. Number of treasury shares at the end of the period

As of September 30, 2026	3,243,961	As of March 31, 2026	3,265,827

c. Average number of shares during the period

First six month of FY2026	37,489,932	First six month of FY2025	38,571,206

* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

Earnings forecasts contained in these materials are based on certain assumptions judged to be reasonable, and on the information available when the forecasts were made. However, the Company makes no guarantee that these forecasts will be achieved. Actual results may differ significantly from the forecasts due to a variety of factors. Please refer to “(3) Consolidated earnings forecasts and others” under “1. Overview of Financial Performance” on page 3 of this earnings report concerning financial forecasts such as the assumptions used for financial forecasts, factors that could cause these assumptions to change, and cautionary notes.

Table of Contents - Attachments

1. Overview of Financial Performance 2
(1) Semi-annual operating results 2
(2) Semi-annual financial position 3
(3) Consolidated earnings forecasts and others 3
2. Semi-annual Consolidated Financial Statements and Primary Notes 4
(1) Semi-annual consolidated balance sheets 4
(2) Semi-annual consolidated statements of income and consolidated statements of comprehensive income 6
Semi-annual consolidated statements of income 6
Semi-annual consolidated statements of comprehensive income 7
(3) Semi-annual consolidated statements of cash flows 8
(4) Notes to semi-annual consolidated financial statements 10
(Notes on the assumption as a going concern) 10
(Notes on significant changes in the amount of shareholders' equity) 10
(Notes on segment information, etc.) 10
(Important subsequent events) 10
3. Other 11
Breakdown of sales 11

1. Overview of Financial Performance

(1) Semi-annual operating results

In the first six months of the fiscal year under review, the Japanese economy continued to show a mild recovery trend due to improvements in the employment and income environment, as well as the effects of various government policies. However, we recognize that it is necessary to pay attention to the impact of the situation in the Middle East, natural disasters, and fluctuations in financial and capital markets and other trends.

Under these economic conditions, in the contract clinical testing industry, FY2026 is a year for the biennial revision of medical service fees under the national health insurance (NHI) system. Although there was no reduction in medical service fees for clinical testing as in the past, the business environment continues to be challenging due to rising costs as well as increasing burdens associated with securing personnel amid labor shortages.

Under these circumstances, despite one fewer business day, net sales for the first six months of the fiscal year under review were ¥78,038 million, an increase of 3.2% year on year, and operating profit was ¥6,046 million, an increase of 2.2% year on year. Ordinary profit was ¥6,335 million, an increase of 3.5% year on year, and profit attributable to owners of parent was ¥4,010 million, a decrease of 4.9% year on year. Net sales increased due to steady progress in acquiring new customers and the promotion of price optimization measures that we have been pursuing. In terms of profit, operating profit and ordinary profit increased due to higher net sales from acquiring new customers and price optimization, despite an increase in depreciation associated with the start of operations for testing equipment in the new wings of the BML General Laboratory. On the other hand, profit decreased in reaction to the gain on sale of non-current assets recorded in the previous fiscal year.

Conditions by business segment are described below.

In the clinical testing business, the BML Group strengthened efforts to acquire new customers and aimed to enhance business performance by implementing activities such as optimizing sales prices and further developing sales to existing customers of items, including new testing items and priority testing items. As a result, net sales in the clinical testing business increased by 3.6% year on year.

In the food hygiene business, we promoted the optimization of trading conditions, with a focus on major customers. Additionally, the amount of orders received for store inspections increased in the food consulting business. Furthermore, the number of microbiological testing contracts in the food testing business remained steady. As a result, net sales in the food hygiene business increased by 2.8% year on year.

As a result of the above, net sales in the testing business overall increased by 3.6% year on year.

In the medical informatics business, although new implementations of electronic medical records increased, net sales decreased by 5.0% year on year due to a decline in replacement projects.

In other businesses, net sales decreased by 8.3% year on year primarily due to a decline in the number of cases acquired in our site management organization (SMO) services for clinical trials at medical institutions, as well as the impact of revisions to medical service fees and a decrease in prescriptions for high-cost drugs in the dispensing pharmacy business.

(2) Semi-annual financial position

(a) Assets, liabilities, and net assets

Regarding the financial position at the end of the first six months of the fiscal year under review, total assets amounted to ¥182,441 million, a ¥806 million decrease over the end of the previous fiscal year, net assets totaled ¥133,748 million, up ¥1,618 million over the end of the previous fiscal year, and the equity ratio was 70.8%, a 1.1 percentage point increase over the end of the previous fiscal year.

The main items contributing to increases or decreases are as follows. In the assets section, cash and deposits decreased by ¥12,260 million, while land increased by ¥9,258 million. In the liabilities section, current liabilities decreased by ¥2,886 million. In the net assets section, retained earnings increased by ¥1,636 million.

(b) Cash flows

Cash and cash equivalents at the end of the first six months of the fiscal year under review decreased by ¥8,959 million from the end of the same period of the previous fiscal year to ¥52,573 million. The cash flow position and factors behind changes for each type of activity are as follows.

Operating activities provided net cash of ¥6,242 million, ¥5,273 million less than in the same period of the previous fiscal year. The main changes included an increase of ¥281 million in depreciation, while profit before income taxes decreased by ¥343 million. In addition, payments for the increase in inventories, payments for the increase in trade receivables, and income taxes paid increased by ¥282 million, ¥295 million, and ¥234 million, respectively, and the change in accrued consumption taxes resulted in a decrease of ¥3,380 million in cash inflow.

Investing activities used net cash of ¥14,863 million, ¥10,150 million more than in the same period of the previous fiscal year. This was mainly due to an increase of ¥8,184 million in purchase of property, plant and equipment.

Financing activities used net cash of ¥3,489 million, ¥5,707 million less than in the same period of the previous fiscal year. This was primarily due to a decrease of ¥5,382 million in purchase of treasury shares.

(3) Consolidated earnings forecasts and others

The Company has not changed its forecasts for consolidated results for the full year announced in the beginning of the fiscal year under review.

2. Semi-annual Consolidated Financial Statements and Primary Notes

(1) Semi-annual consolidated balance sheets

(Millions of yen)

	As of March 31, 2026	As of September 30, 2026
Assets		
Current assets		
Cash and deposits	68,029	55,769
Notes and accounts receivable - trade	26,827	27,852
Merchandise and finished goods	334	431
Work in process	904	1,088
Raw materials and supplies	3,605	3,665
Other	2,066	1,773
Allowance for doubtful accounts	(60)	(67)
Total current assets	101,707	90,513
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	29,913	30,513
Land	16,117	25,375
Other, net	17,495	15,955
Total property, plant and equipment	63,527	71,845
Intangible assets		
Other	4,695	4,758
Total intangible assets	4,695	4,758
Investments and other assets		
Other	13,395	15,388
Allowance for doubtful accounts	(78)	(64)
Total investments and other assets	13,317	15,324
Total non-current assets	81,539	91,927
Total assets	183,247	182,441

(Millions of yen)

	As of March 31, 2026	As of September 30, 2026
Liabilities		
Current liabilities		
Notes and accounts payable - trade	20,229	20,984
Income taxes payable	2,197	2,268
Provision for bonuses	3,918	4,064
Other	14,542	10,684
Total current liabilities	40,887	38,001
Non-current liabilities		
Retirement benefit liability	6,347	6,455
Provision for retirement benefits for directors (and other officers)	203	160
Other	3,679	4,075
Total non-current liabilities	10,230	10,691
Total liabilities	51,117	48,693
Net assets		
Shareholders' equity		
Share capital	6,045	6,045
Capital surplus	6,646	6,657
Retained earnings	120,945	122,582
Treasury shares	(9,157)	(9,096)
Total shareholders' equity	124,480	126,188
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	706	777
Remeasurements of defined benefit plans	2,458	2,292
Total accumulated other comprehensive income	3,165	3,069
Share acquisition rights	21	18
Non-controlling interests	4,461	4,471
Total net assets	132,129	133,748
Total liabilities and net assets	183,247	182,441

(2) Semi-annual consolidated statements of income and consolidated statements of comprehensive income

Semi-annual consolidated statements of income

(Millions of yen)

	Six Months Ended September 30, 2025 (April 1, 2025 to September 30, 2025)	Six Months Ended September 30, 2026 (April 1, 2026 to September 30, 2026)
Net sales	75,628	78,038
Cost of sales	50,475	52,196
Gross profit	25,152	25,841
Selling, general and administrative expenses	19,237	19,795
Operating profit	5,915	6,046
Non-operating income		
Dividend income	75	77
Interest income	49	77
Other	175	221
Total non-operating income	300	377
Non-operating expenses		
Interest expenses	59	63
Other	37	25
Total non-operating expenses	97	88
Ordinary profit	6,118	6,335
Extraordinary income		
Gain on sale of non-current assets	539	1
Gain on sale of investment securities	–	1
Total extraordinary income	539	3
Extraordinary losses		
Loss on retirement of non-current assets	5	20
Impairment losses	28	36
Total extraordinary losses	33	57
Profit before income taxes	6,624	6,281
Income taxes - current	2,161	2,079
Income taxes - deferred	104	34
Total income taxes	2,265	2,114
Profit	4,358	4,167
Profit attributable to non-controlling interests	139	156
Profit attributable to owners of parent	4,219	4,010

Semi-annual consolidated statements of comprehensive income

(Millions of yen)

	Six Months Ended September 30, 2025 (April 1, 2025 to September 30, 2025)	Six Months Ended September 30, 2026 (April 1, 2026 to September 30, 2026)
Profit	4,358	4,167
Other comprehensive income		
Valuation difference on available-for-sale securities	173	70
Remeasurements of defined benefit plans, net of tax	(76)	(167)
Total other comprehensive income	97	(97)
Comprehensive income	4,455	4,070
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	4,316	3,914
Comprehensive income attributable to non-controlling interests	139	155

(3) Semi-annual consolidated statements of cash flows

(Millions of yen)

	Six Months Ended September 30, 2025 (April 1, 2025 to September 30, 2025)	Six Months Ended September 30, 2026 (April 1, 2026 to September 30, 2026)
Cash flows from operating activities		
Profit before income taxes	6,624	6,281
Depreciation	4,329	4,611
Impairment losses	28	36
Interest and dividend income	(125)	(155)
Interest expenses	59	63
Decrease (increase) in trade receivables	(700)	(996)
Decrease (increase) in inventories	(55)	(337)
Increase (decrease) in trade payables	722	754
Increase (decrease) in provision for bonuses	261	145
Decrease (increase) in consumption taxes refund receivable	1,301	16
Increase (decrease) in accrued consumption taxes	1,268	(2,112)
Other, net	(677)	(184)
Subtotal	13,037	8,122
Interest and dividends received	254	152
Interest paid	(60)	(64)
Income taxes paid	(1,814)	(2,049)
Other, net	99	81
Net cash provided by (used in) operating activities	11,515	6,242
Cash flows from investing activities		
Payments into time deposits	(2,613)	(3,808)
Proceeds from withdrawal of time deposits	2,783	2,784
Purchase of property, plant and equipment	(4,594)	(12,779)
Purchase of intangible assets	(869)	(979)
Proceeds from sale of property, plant and equipment	701	17
Other, net	(121)	(98)
Net cash provided by (used in) investing activities	(4,713)	(14,863)

(Millions of yen)

	Six Months Ended September 30, 2025 (April 1, 2025 to September 30, 2025)	Six Months Ended September 30, 2026 (April 1, 2026 to September 30, 2026)
Cash flows from financing activities		
Repayments of lease liabilities	(903)	(907)
Dividends paid	(2,730)	(2,436)
Dividends paid to non-controlling interests	(180)	(145)
Purchase of treasury shares	(5,382)	–
Other, net	0	0
Net cash provided by (used in) financing activities	(9,196)	(3,489)
Net increase (decrease) in cash and cash equivalents	(2,394)	(12,111)
Cash and cash equivalents at beginning of period	63,928	64,602
Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries	–	82
Cash and cash equivalents at end of period	61,533	52,573

(4) Notes to semi-annual consolidated financial statements

(Notes on the assumption as a going concern)

Six months ended September 30, 2026 (From April 1, 2026 to September 30, 2026)

Not applicable

(Notes on significant changes in the amount of shareholders' equity)

Six months ended September 30, 2026 (From April 1, 2026 to September 30, 2026)

Not applicable

(Notes on segment information, etc.)

[Segment information]

I. Six months ended September 30, 2025 (From April 1, 2025 to September 30, 2025)

1. Information about net sales and profit or loss by reportable segment

Since information related to the business other than the reportable "testing business" segment is deemed immaterial, separate disclosure of the information is omitted.

2. Disclosure of impairment losses on non-current assets or goodwill, etc. for each reportable segment

Since the information is deemed immaterial, separate disclosure of the information is omitted.

II. Six months ended September 30, 2026 (From April 1, 2026 to September 30, 2026)

1. Information about net sales and profit or loss by reportable segment

Since information related to the business other than the reportable "testing business" segment is deemed immaterial, separate disclosure of the information is omitted.

2. Disclosure of impairment losses on non-current assets or goodwill, etc. for each reportable segment

Since the information is deemed immaterial, separate disclosure of the information is omitted.

(Important subsequent events)

(Acquisition of own shares and cancellation of treasury shares)

At the Board of Directors meeting held on November 11, 2026, the Company resolved to acquire its own shares pursuant to the provisions of Article 156 of the Companies Act, as applied by replacing the relevant terms pursuant to the provisions of Article 165, Paragraph 3 of the same Act, and also resolved to cancel treasury shares pursuant to the provisions of Article 178 of the same Act. Details are as follows.

(1) Reason for acquisition of own shares

The Company will acquire its own shares in order to enhance capital efficiency and improve shareholder returns.

(2) Details of the Board of Directors' resolution concerning the acquisition of own shares

(i) Class of shares to be acquired: Common stock of the Company

(ii) Total number of shares to be acquired: 1,500,000 shares (maximum)

(iii) Total amount of share acquisition costs: 5,000 million yen (maximum)

(iv) Scheduled acquisition date: From November 12, 2026 to September 30, 2027

(v) Method of acquisition: Market purchases in the floor trading market under a discretionary transaction contract

(3) Details of the Board of Directors' resolution concerning the cancellation of treasury shares

(i) Class of shares to be cancelled: Common stock of the Company

(ii) Total number of shares to be cancelled: All own shares acquired as described in item (2) above

(iii) Scheduled cancellation date: October 29, 2027

3. Other

Breakdown of sales

Testing		Six Months Ended September 30, 2025		Six Months Ended September 30, 2026		Change (%)
		¥ million	% of total	¥ million	% of total	
Testing business	Clinical testing business					
	Biochemical tests	29,176	38.6	30,181	38.7	3.4
	Hematological tests	6,153	8.1	6,330	8.1	2.9
	Immunological tests	15,229	20.1	15,192	19.5	(0.2)
	Microbiological tests	3,737	4.9	4,038	5.2	8.1
	Pathological tests	5,244	6.9	5,659	7.3	7.9
	Other tests	10,140	13.4	10,815	13.9	6.7
	(Clinical testing business subtotal)	69,681	92.1	72,218	92.5	3.6
	Food hygiene business	2,516	3.3	2,586	3.3	2.8
	Testing business subtotal	72,197	95.5	74,805	95.9	3.6
Medical informatics business		2,665	3.5	2,531	3.2	(5.0)
Other businesses		765	1.0	701	0.9	(8.3)
Total		75,628	100.0	78,038	100.0	3.2